Некоторое содержание этого приложения в настоящий момент недоступно.
Если эта ситуация сохраняется, свяжитесь с нами по адресуОтзывы и контакты
1. (WO2010071582) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT
Примечание: Текст, основанный на автоматизированных процессах оптического распознавания знаков. Для юридических целей просьба использовать вариант в формате PDF

CLAIMS

1. A pharmaceutical product comprising, in combination, a first active ingredient which is a muscarinic antagonist selected from: anf/-[(1S,2R)-2-(2-Hydroxy-2,2-di-thiophen-2-yl-acetoxy)-bicyclo[2.2.1]hept-7-yl]-trimethyl-ammonium X; and a/tf/-(1 S, 2R) 2-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-bicyclo[2.2.1]hept-7-yl]-dimethyl-(3-phenoxy-propyl)-ammonium X; wherein X represents a pharmaceutically acceptable anion of a mono or polyvalent acid, and a second active ingredient which is selected from i) a phosphodiesterase inhibitor, ii) a modulator of chemokine receptor function, iii) an inhibitor of kinase function, iv) a protease inhibitor, v) a steroidal glucocorticoid receptor agonist, vi) a non-steroidal glucocorticoid receptor agonist, and vii) a purinoceptor antagonist.

2. A product according to claim 1 wherein the first active ingredient is a muscarinic antagonist, which is a bromide salt.

3. A product according to claim 1 or claim 2, wherein the second active ingredient is a CCR1 antagonist.

4. A product according to claim 3 wherein the second active ingredient is a CCR1 antagonist, selected from:

Λ/-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide;

Λ/-{5-chloro-2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide;

2-{2-chloro-5-{[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-[(methylamino)carbonyl]phenoxy}-2-methylpropanoic acid; or pharmaceutically acceptable salts thereof.

5. A product according to claim 4, wherein the second active ingredient is Λ/-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide or a pharmaceutically acceptable salt thereof.

6. A product according to claim 4, wherein the second active ingredient is Λ/-{5-chloro-2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methylpropyl)oxy]-4-hydroxyphenyl}acetamide or a pharmaceutically acceptable salt thereof.

7. A product according to claim 4, wherein the second active ingredient is 2-{2-chloro-5-{[(2S)-3-(5-chloro-1 'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4- [(methylamino)carbonyl]phenoxy}-2-methylpropanoic acid or a pharmaceutically acceptable salt thereof.

8. A product according to claim 1 or claim 2, wherein the second active ingredient is a steroidal glucocorticoid receptor agonist.

9. Use of a product according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of a respiratory disease.

10. Use according to claim 9, wherein the respiratory disease is chronic obstructive pulmonary disease.

11. A method of treating a respiratory disease, which method comprises simultaneously, sequentially or separately administering: (a) a (therapeutically effective) dose of a first active ingredient which is a muscarinic receptor antagonist as defined in claim 1 or claim 2; and

(b) a (therapeutically effective) dose of a second active ingredient as defined in claim 1 ; to a patient in need thereof.

12. A kit comprising a preparation of a first active ingredient which is a muscarinic receptor antagonist as defined in claim 1 or claim 2, and a preparation of a second active ingredient as defined in claim 1 and optionally instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.

13. A pharmaceutical composition comprising, in admixture, a first active ingredient which is a muscarinic receptor antagonist as defined in claim 1 or claim 2 and a second active ingredient as defined in claim 1.